Status:
ACTIVE_NOT_RECRUITING
Low Molecular Weight Heparin vs Direct Oral Anticoagulant After Bariatric Surgery
Lead Sponsor:
Cairo University
Conditions:
Deep Venous Thrombosis
Eligibility:
All Genders
Phase:
PHASE1
Brief Summary
Extended Venous Thromboemboism Prophylaxis After Bariatric Surgeries: A Comparison Of Low Molecular Weight Heparin With Direct Oral Anticoagulant
Detailed Description
This study aims to compare the effectiveness of rivaroxaban versus low molecular weight heparin in reducing the incidence of PMVT after bariatric surgery.
Eligibility Criteria
Inclusion
- \- BARIATRIC PATIENTS
Exclusion
- BLEEDING TENDENCY
Key Trial Info
Start Date :
March 25 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06913595
Start Date
March 25 2024
End Date
November 1 2025
Last Update
August 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cairo University
Cairo, Egypt, 11511